German radiopharmaceutical firm ITM Isotope Technologies Munich and Navigo Proteins are teaming up to develop a fibroblast activation protein (FAP)-targeted radiopharmaceutical program for the treatment of solid tumors.
Navigo develops optimized scaffold protein-based affinity ligands called Affilin molecules, the companies said. Under the agreement, Navigo's protein engineering platform will be used to develop and select a FAP-targeting Affilin molecule, which will be paired with a therapeutic radioisotope provided by ITM. Following the selection, ITM will have exclusive rights to further develop the radiolabeled FAP-specific Affilin through clinical testing in potentially multiple cancer indications.
The agreement also includes a nonexclusive license for diagnostic use in radioimaging.
